Cite
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials.
MLA
Heerspink, Hiddo J. L., et al. “Estimated Lifetime Benefit of Novel Pharmacological Therapies in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Joint Analysis of Randomized Controlled Clinical Trials.” Diabetes, Obesity & Metabolism, vol. 25, no. 11, Nov. 2023, pp. 3327–36. EBSCOhost, https://doi.org/10.1111/dom.15232.
APA
Heerspink, H. J. L., Vart, P., Jongs, N., Neuen, B. L., Bakris, G., Claggett, B., Vaduganathan, M., McCausland, F., Docherty, K. F., Jhund, P. S., Solomon, S. D., Perkovic, V., & McMurray, J. J. V. (2023). Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials. Diabetes, Obesity & Metabolism, 25(11), 3327–3336. https://doi.org/10.1111/dom.15232
Chicago
Heerspink, Hiddo J L, Priya Vart, Niels Jongs, Brendon L Neuen, George Bakris, Brian Claggett, Muthiah Vaduganathan, et al. 2023. “Estimated Lifetime Benefit of Novel Pharmacological Therapies in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Joint Analysis of Randomized Controlled Clinical Trials.” Diabetes, Obesity & Metabolism 25 (11): 3327–36. doi:10.1111/dom.15232.